Lynx Capital 德石资本
Healthcare Focus, Global Resource, China Angle
Who We Are
Lynx Capital is a healthcare and life science -focused fund, investing in innovative companies in western countries in both therapeutics and medical technology areas, with a potential to collaborate with Chinese companies to explore the China market. With the extensive expertise and experience in both China and the States, and deep understanding of healthcare and business, Lynx Capital believes that it is well positioned to help with such collaboration.
BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 28, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory disease therapy AUP-16 in Greater China. Shanghai-based Lynx Financial served as Aurealis' exclusive financial advisor in this transaction.